Tyrosine kinase inhibitors in treatment of fibrous histiocytoma
Aim: To describe potential beneficial effects of tyrosine kinase inhibitor in the treatment of unresectable/metastatic fibrous histiocytoma. Methods: We report a case of advanced stage fibrous histiocytoma with locally recurrent disease plus lung and bone metastatic deposits. Patient was treated w...
Збережено в:
| Дата: | 2009 |
|---|---|
| Автори: | , , , , |
| Формат: | Стаття |
| Мова: | English |
| Опубліковано: |
Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України
2009
|
| Назва видання: | Experimental Oncology |
| Теми: | |
| Онлайн доступ: | http://dspace.nbuv.gov.ua/handle/123456789/135111 |
| Теги: |
Додати тег
Немає тегів, Будьте першим, хто поставить тег для цього запису!
|
| Назва журналу: | Digital Library of Periodicals of National Academy of Sciences of Ukraine |
| Цитувати: | Tyrosine kinase inhibitors in treatment of fibrous histiocytoma / D. Mauri, C. Panou, A. Valachis, K. Kamposioras, L. Tsali // Experimental Oncology. — 2009. — Т. 31, № 1. — С. 60-61. — Бібліогр.: 18 назв. — англ. |
Репозитарії
Digital Library of Periodicals of National Academy of Sciences of Ukraine| id |
irk-123456789-135111 |
|---|---|
| record_format |
dspace |
| spelling |
irk-123456789-1351112018-06-15T03:10:12Z Tyrosine kinase inhibitors in treatment of fibrous histiocytoma Maur, D. Panou, C. Valachis, A. Kamposioras, K. Tsali, L. Short communications Aim: To describe potential beneficial effects of tyrosine kinase inhibitor in the treatment of unresectable/metastatic fibrous histiocytoma. Methods: We report a case of advanced stage fibrous histiocytoma with locally recurrent disease plus lung and bone metastatic deposits. Patient was treated with the tyrosine kinase inhibitor sunitinib. Results: Treatment with Sunitinib resulted in disease stabilization in the regional lesion and in good partial response for metastatic foci (reduction in number and size). After 13 months of treatment the patient is doing well with no tumor progression. Conclusions: This case appears to be one of the first documentations of beneficial effect and potential long-term benefit of TKIs in the treatment of fibrous histiocytoma. 2009 Article Tyrosine kinase inhibitors in treatment of fibrous histiocytoma / D. Mauri, C. Panou, A. Valachis, K. Kamposioras, L. Tsali // Experimental Oncology. — 2009. — Т. 31, № 1. — С. 60-61. — Бібліогр.: 18 назв. — англ. 1812-9269 http://dspace.nbuv.gov.ua/handle/123456789/135111 en Experimental Oncology Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України |
| institution |
Digital Library of Periodicals of National Academy of Sciences of Ukraine |
| collection |
DSpace DC |
| language |
English |
| topic |
Short communications Short communications |
| spellingShingle |
Short communications Short communications Maur, D. Panou, C. Valachis, A. Kamposioras, K. Tsali, L. Tyrosine kinase inhibitors in treatment of fibrous histiocytoma Experimental Oncology |
| description |
Aim: To describe potential beneficial effects of tyrosine kinase inhibitor in the treatment of unresectable/metastatic fibrous histiocytoma.
Methods: We report a case of advanced stage fibrous histiocytoma with locally recurrent disease plus lung and bone
metastatic deposits. Patient was treated with the tyrosine kinase inhibitor sunitinib. Results: Treatment with Sunitinib resulted in
disease stabilization in the regional lesion and in good partial response for metastatic foci (reduction in number and size). After
13 months of treatment the patient is doing well with no tumor progression. Conclusions: This case appears to be one of the first
documentations of beneficial effect and potential long-term benefit of TKIs in the treatment of fibrous histiocytoma. |
| format |
Article |
| author |
Maur, D. Panou, C. Valachis, A. Kamposioras, K. Tsali, L. |
| author_facet |
Maur, D. Panou, C. Valachis, A. Kamposioras, K. Tsali, L. |
| author_sort |
Maur, D. |
| title |
Tyrosine kinase inhibitors in treatment of fibrous histiocytoma |
| title_short |
Tyrosine kinase inhibitors in treatment of fibrous histiocytoma |
| title_full |
Tyrosine kinase inhibitors in treatment of fibrous histiocytoma |
| title_fullStr |
Tyrosine kinase inhibitors in treatment of fibrous histiocytoma |
| title_full_unstemmed |
Tyrosine kinase inhibitors in treatment of fibrous histiocytoma |
| title_sort |
tyrosine kinase inhibitors in treatment of fibrous histiocytoma |
| publisher |
Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України |
| publishDate |
2009 |
| topic_facet |
Short communications |
| url |
http://dspace.nbuv.gov.ua/handle/123456789/135111 |
| citation_txt |
Tyrosine kinase inhibitors in treatment of fibrous histiocytoma / D. Mauri, C. Panou, A. Valachis, K. Kamposioras, L. Tsali // Experimental Oncology. — 2009. — Т. 31, № 1. — С. 60-61. — Бібліогр.: 18 назв. — англ. |
| series |
Experimental Oncology |
| work_keys_str_mv |
AT maurd tyrosinekinaseinhibitorsintreatmentoffibroushistiocytoma AT panouc tyrosinekinaseinhibitorsintreatmentoffibroushistiocytoma AT valachisa tyrosinekinaseinhibitorsintreatmentoffibroushistiocytoma AT kamposiorask tyrosinekinaseinhibitorsintreatmentoffibroushistiocytoma AT tsalil tyrosinekinaseinhibitorsintreatmentoffibroushistiocytoma |
| first_indexed |
2025-07-09T22:43:43Z |
| last_indexed |
2025-07-09T22:43:43Z |
| _version_ |
1837211084785713152 |
| fulltext |
60 Experimental Oncology 31, 60–61, 2009 (March)
Malignant fibrous histiocytoma is a common form
of soft-tissue sarcoma in adulthood [1]. Surgical
management remains the cornerstone of therapy for
soft tissue sarcomas. Unfortunately, approximately
40% of patients with soft tissue sarcoma will develop
local or distant disease recurrences [2], and systemic
chemotherapy with palliative intent is conventionally
used to treat the metastatic disease [3].
Targeted biological treatment with the use of tyrosine ki-
nase inhibitors (TKIs) entered medical oncology practice the
last decade. The advances in understanding the molecular
biology of many sarcomas have led to the development of
new targeted treatment options. Imatinib is a small molecule
inhibitor that blocks the aberrant tyrosine kinase activity
of the BCR-ABL fusion oncoprotein, and it is the actual
standard of care in the management of unresectable and
metastatic gastrointestinal stromal tumors (GIST) [4, 5].
Sunitinib is an oral multitargeted tyrosine kinase
inhibitor of vascular endothelial growth factor recep-
tor (VEGFR), platelet-derived growth factor receptor
(PDGFR), c-Kit, and FLT-3 kinase, that has potent anti-
angiogenic and antitumour activities [6, 7]. Treatment
with sunitinib is actually recommended in the manage-
ment of renal cancer [8, 9] and second line treatment
of gastrointestinal stromal tumors [10].
Herein, we describe a case of metastatic fibrous his-
tiocytoma successfully treated with sunitinib. In July 2008,
a 62 year-old man came at the ambulatory department
for a second opinion for management of side effects of
TKIs treatment. The patient reported he was treated with
Sunitinib (50 mg once daily for four weeks followed by two
weeks rest) and referred weight loss with a reduced ap-
petite, dermatologic lesions, symptoms of neuropathy and
severe mucositis. Clinical evaluation revealed hand and
foot syndrome-grade 3, gingivitis-grade 2–3 and anemia.
Full blood count showed macrocytic anemia, while the rest
of the biochemical blood exams were normal.
Patient referred having renal cancer since Februa-
ry 2005 for which he had undergone a left kidney nephre-
ctomy in April 2005. He reported that the neoplastic mass
was invading the small intestine, with no renal vessels
invasion or regional lymph node involvement. After the
operation, oncologists recommended adjuvant treatment
with adriamycin and iphosphamide, which he refused. In
June 2007, chest and upper abdominal CT scans revealed
local relapse, metastases in both lungs and bone involve-
ment. Treatment with Sunitinib and bisphosphonates was
initiated. Long lasting objective responses were observed
in both bone and lung metastases and disease stabilization
was observed in the regional relapse. In August 2008, the
patient was still responding to treatment (Figure).
In general, renal cancer does not infiltrate the small
intestine. Moreover, the absence of local lymphadenopa-
thy and blood vessel invasion, as well as the indication
of adjuvant intravenous chemotherapy for renal cancer,
indicated a diagnostic-therapeutic bias. Indeed, the
referred diagnosis of renal cancer did not cope with
patient’s disease report. Therefore, patient was asked
to submit the nephrectomy pathology report on the fol-
lowing visit. A malignant fibrous histiocytoma, invading
the lower pole of the left kidney, the perinephric adipose
tissue and the small intestine was reported. No evidence
of renal adenocarcinoma was found from patient’s
medical-chart audit. Despite the diagnostic-therapeutic
bias and the fact that, tyrosine kinase inhibitors are not
recommended for the treatment of malignant fibrous
histiocytoma, the patient is doing well, with a 13 months
progression free interval. Due to the patient’s clinical
response, continuation of the treatment was decided.
Sunitinib side effects were managed with dose reduction
to 37.5 mg per day and administration of oral pyridoxine
and benzydamine hydrochloride mouthwash.
At our knowledge, this case represents the third
report presenting clinical beneficial effects of TKIs in
the treatment of fibrous histiocytoma and the second
one documenting the potential long term benefit of the
treatment. Indeed, two previous studies including 13 and
11 fibrous histiocytoma patients, respectively, evidenced
TYROSINE KINASE INHIBITORS IN TREATMENT OF FIBROUS
HISTIOCYTOMA
D. Mauri1, *, C. Panou2, A. Valachis1, K. Kamposioras1, L. Tsali1
1Panhellenic Association for Continual Medical Research (PACMeR), Section of Medical Oncology,
Roditsa TK35100, Lamia, Greece
2Department of Urology, General Hospital of Lamia, Lamia TK35100, Greece
Aim: To describe potential beneficial effects of tyrosine kinase inhibitor in the treatment of unresectable/metastatic fibrous his-
tiocytoma. Methods: We report a case of advanced stage fibrous histiocytoma with locally recurrent disease plus lung and bone
metastatic deposits. Patient was treated with the tyrosine kinase inhibitor sunitinib. Results: Treatment with Sunitinib resulted in
disease stabilization in the regional lesion and in good partial response for metastatic foci (reduction in number and size). After
13 months of treatment the patient is doing well with no tumor progression. Conclusions: This case appears to be one of the first
documentations of beneficial effect and potential long-term benefit of TKIs in the treatment of fibrous histiocytoma.
Key Words: tyrosine kinase inhibitors, sunitinib, fibrous histiocytoma, sarcoma.
Received: October 16, 2008.
*Correspondence: E-mail: dvd.mauri@gmail.com
Abbreviations used: PDGFR — platelet-derived growth factor
receptor; TKIs — tyrosine kinase inhibitors.
Exp Oncol 2009
31, 1, 60–61
Experimental Oncology 31, 60–61, 2009 (March) 61
high percent of stable disease but no complete or partial
responders [11, 16]. These reports represent an important
cornerstone, to trigger and extend the research on the role
of TKIs in the treatment of diffe rent types of sarcoma.
a
b
Figure. Pulmonary metastases before treatment (a) and after
treatment with tyrosine kinase inhibitors for 13 months (b). No-
table reduction in number and size of pulmonary metastases
during the course of Sunitinib treatment was observed
As a matter of fact, the TKIs’ beneficial effects re-
ported in our patient should not surprise. TKIs are the
treatment of choice for gastrointestinal stromal tumor in
both 1st and 2nd line setting [10, 12]. Furthermore, there
are few recent reports outlining the potential value of su-
nitinib and other multitargeted tyrosine kinase inhibitors,
such as sorafenib and pazopanib, for treating subtypes of
sarcomas other than fibrous histiocytoma [13–17]. More-
over, preclinical data evidenced that imatinib mesylate
reduced tumor growth of fibrous histiocytoma cell lines
expressing PDGFR and c-Kit [18]. Thereafter, the pos-
sibility that TKI may effectively work on patients affected
by malignant fibrous histiocytoma is consistent.
Anyhow, despite the positive effects observed, we
discourage deliberate administration of TKIs for treat-
ment of fibrous histiocytoma, until TKIs will be clearly
indicated for the treatment of the disease. Thereafter,
their use should be considered still investigatory and
not tried out of strict research protocols.
Nevertheless, pour considering the limits of our report,
it is only a retrospective case (identified by medical chart
audit), characterized by TKIs administration out of a strict
research protocol, we believe that, the observed good re-
sponse and long lasting beneficious effects should be taken
into consideration. This case may be an important step
for the treatment of these sarcomas. Extensive controlled
research has to be conducted to confirm these findings.
REFERENCES
1. Coindre JM, Terrier P, Guillou L, et al. Predictive value of grade
for metastasis development in the main histologic types of adult soft
tissue sarcomas: a study of 1240 patients from the French Federation
of Cancer Centers Sarcoma Group. Cancer 2001; 91: 1914–26.
2. Weitz J, Antonescu CR, Brennan MF. Localized extremi
ty soft tissue sarcoma: improved knowledge with unchanged
survival over time. J Clin Oncol 2003; 21: 2719–25.
3. Cormier JN, Pollock RE. Soft tissue sarcomas. CA Can
cer J Clin 2004; 54: 94–109.
4. Demetri GD, von Mehren M, Blanke CD, et al. Efficacy
and safety of imatinib mesylate in advanced gastrointestinal
stromal tumors. N Engl J Med 2002; 347: 472–80.
5. Verweij J, Casali PG, Zalcberg J, et al. Progressionfree
survival in gastrointestinal stromal tumours with highdose
imatinib: randomised trial. Lancet 2004; 364: 1127–34.
6. O’Farrell AM, Abrams TJ, Yuen HA, et al. SU11248 is
a novel FLT3 tyrosine kinase inhibitor with potent activity
in vitro and in vivo. Blood 2003; 101: 3597–605.
7. Mendel DB, Laird AD, Xin X, et al. In vivo antitumor
activity of SU11248, a novel tyrosine kinase inhibitor targeting
vascular endothelial growth factor and plateletderived growth
factor receptors: determination of a pharmacokinetic/pharma
codynamic relationship. Clin Cancer Res 2003; 9: 327–37.
8. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced
clearcell renalcell carcinoma. N Engl J Med 2007; 356: 125–34.
9. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib ver
sus interferon alfa in metastatic renalcell carcinoma. N Engl
J Med 2007; 356: 115–24.
10. Demetri GD, van Oosterom AT, Garrett CR, et al. Effi
cacy and safety of sunitinib in patients with advanced gastroin
testinal stromal tumour after failure of imatinib: a randomised
controlled trial. Lancet 2006; 368: 1329–38.
11. Vigil CE, Chiappori AA, Williams CA, et al. Phase II
study of sunitinib malate (SM) in subjects with metastatic
and/or surgically unresectable nonGIST soft tissue sarcomas.
J Clin Oncol 2008; 26 Suppl (Abstract 10535): 561.
12. Joensuu H, Roberts PJ, Sarlomo-Rikala M, et al. Effect of
the tyrosine kinase inhibitor STI571 in a patient with a metastatic
gastrointestinal stromal tumor N Engl J Med 2001; 344: 1052–6.
13. Arnaud L, Schartz NE, Bousquet G, et al. Transient
sunitinibinduced coma in a patient with fibromyxoid sarcoma.
J Clin Oncol 2008; 26: 1569–71.
14. Sleijfer S, Papai A, Le Cesne M, et al. Phase II study
of pazopanib (GW786034) in patients (pts) with relapsed or
refractory soft tissue sarcoma (STS): EORTC 62043. J Clin
Oncol 2007; 25 Suppl (Abstract 10031): 552
15. Faivre S, Delbaldo C, Vera K, et al. Safety, pharma
cokinetic, and antitumor activity of SU11248, a novel oral
multitarget tyrosine kinase inhibitor, in patients with cancer.
J Clin Oncol 2006; 24: 25–35.
16. D’Adamo DR, Keohan M, Schuetze S, et al. Clinical results
of a phase II study of sorafenib in patients (pts) with nonGIST sar
comas (CTEP study #7060). J Clin Oncol 2007; 25 Suppl: 10001.
17. Ryan CW, von Mehren M, Rankin CJ, et al. Phase II inter
group study of sorafenib (S) in advanced soft tissue sarcomas (STS):
SWOG 0505. J Clin Oncol 2008; 26 Suppl (Abstract 10532): 561
18. Irsan I, Akisue T, Hara H, et al. Imatinib mesylate
inhibits tumorigenicity of malignant fibrous histiocytoma cells
in vivo. Anticancer Res 2007; 27: 423–9.
Copyright © Experimental Oncology, 2009
|